Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma

New England Journal of Medicine

Volumn 334, Issue 8, 1996, Pages 488-493

  Berenson, James R ^a,n   Lichtenstein, Alan ^a   Porter, Lester ^b   Dimopoulos, Meletios A ^c   Bordoni, Roldolfo ^d,k   George, Sebastian ^e   Lipton, Allan ^f   Keller, Alan ^g   Ballester, Oscar ^h   Kovacs, Michael J ⁱ   Blacklock, Hilary A ^j   Bell, Richard ^d,k   Simeone, Joseph ^l   Reitsma, Dirk J ^m   Heffernan, Maika ^m   Seaman, John ^m   Knight, Robert D ^m  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAINT THOMAS HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d American Cardiovascular Research Institute   (United States)

^e SW Institute of Clinical Research ^*  (United States)

^f PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^g Cancer Care Associates   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ LONDON HEALTH SCIENCES CENTRE   (Canada)

^j MIDDLEMORE HOSPITAL   (New Zealand)

^k ST JOHN OF GOD HOSPITAL   (Australia)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

^m NOVARTIS PHARMA AG   (Switzerland)

ⁿ VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PAMIDRONIC ACID;

ARTICLE; BONE DISEASE; BONE PAIN; BONE RADIOGRAPHY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD COMPRESSION;

AGED; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; HYPERCALCEMIA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOLYSIS; PAIN; SPINAL CORD COMPRESSION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 9044219839     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199602223340802     Document Type: Article

References (33)

1. Mundy GR, Bertolini DR. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986;13:291-9. [Erratum, Semin Oncol 1986; 13:lxiii.]
2. Kyle RA Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975;50. 29-40
3. Kanis JA, McCloskey EV, Taube T, O'Rourke N. Rationale for the use of bisphosphonates in bone metastases. Bone 1991;12:Suppl 1.S13-S18.
4. Mundy GR Mechanisms of osteolytic hone destruction. Bone 1991;12 Suppl 1:S1-S6.
5. Stashenko P, Dewhirst FE, Peros WJ, Kent RL, Ago JM. Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphocoxin in bone resorption. J Immunol 1987;138:1464-8.
6. Fleisch H. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. In: Brunner KW, Fleisch H. Senn H-J, eds. Bisphosphonates and tumor osteolysis. Vol 116 of Recent results in cancer research. Berlin, Germany. Springer-Verlag, 1989:1-28
7. Coleman RE, Purohit OP Osteoclast inhibition for the treatment of bone metastases Cancer Treat Rev 1993;19:79-103
8. Belch AR, Bergsagel DE, Wilson K, et al Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991;9:1397-402
9. Siris ES, Sherman WH, Baquiran DC, Schlatterer JP, Osserman EF, Canfield RE Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma N Engl J Med 1980;302:310-5.
10. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992;340:1049-52 [Erratum, Lancet 1992;340:1420.]
11. Kellihan MJ, Mangino PD Pamidronate. Ann Pharmacother 1992;26:1262-9
12. Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993;95:297-304.
13. Man Z, Otero AB, Rendo P, Barazzutti L, Avalos JCS. Use of pamidronate for multiple myeloma osteolytic lesions. Lancet 1990;335:663.
14. Thiebaud D, Leyvraz S, von Fliedner V, et al. Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991;27:37-41.
15. Durie BGM, Salmon SE A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36.842-54.
16. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases final results of the Study by the Radiation Therapy Oncology Group. Cancer 1982;50:893-9.
17. Beahrs OH, Henson DE, Hutter RVP, Myers MH, eds. Manual for staging of cancer 3rd ed. Philadelphia: J.B Lippincott, 1988.
18. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians J Chronic Dis 1981;34:585-97.
19. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland Cancer 1977;39:1289-94.
20. Kyle RA, Jowsey J, Kelly PJ, Taves DR Multiple-myeloma bone disease: the comparative effect of sodium fluoride and calcium carbonate or placebo. N Engl J Med 1975;293:1334-8
21. Alexanian R, Yap BS, Bodey GP Prednisone pulse therapy for refractory myeloma. Blood 1983,62:572-7
22. Acute Leukemia Group B, Eastern Cooperative Oncology Group Ineffectiveness of fluoride therapy in multiple myeloma. N Engl J Med 1972;286:1283-8.
23. Cohen HJ, Silberman HR, Tornyos K, Bartolucci AA. Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. Blood 1984;63:639-48.
24. Cheung WK, Hone F, Schoenfeld S, et al. A single-dose bioavailability study of pamidronate disodium after oral administration as encapsulated enteric-coated pellets, enteric-coated tablets, and a solution to patients with postmenopausal osteoporosis. Am J Ther 1994;1:221-7.
25. Aranko K, Hanhijarvi H, Humphreys M, Drake J, Lawton WA. Beneficial effects of oral clodronate in the management of malignant osteolysis and hypercalcaemia. Bone 1995;16:275-6.
26. van Breukelen FJM, Bijvoet OLM, van Oosterom AT. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (A PD.). Lancet 1979;1:803-5.
27. Bergsagel DE. Controversies in the treatment of plasma cell myeloma. Postgrad Med J 1985;61:109-16.
28. Salmon SE, Cassady JR. Plasma cell neoplasms. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology. 4th ed. Vol. 2. Philadelphia: J.B. Lippincott, 1993:1984-2054.
29. Weber DM, Alexanian R. Multiple myeloma and other plasma cell dyserasias In: Pazdur R, ed. Medical oncology: a comprehensive review Huntington, N.Y.: PRR, 1993:49-58.
30. Alexanian R, Dreicer R. Chemotherapy for multiple myeloma Cancer 1984;53:583-8.
31. Ferretti JL, Cointry G, Capozza R, Montuori E, Roldan E, Lloret AP. Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) on femur diaphyses and cortical bone tissue in rats. Bone Miner 1990;11:111-22.
32. Ferretti JL, Delgado CJ, Capozza RF, et al. Protective effects of disodium etidronate and pamidronate against the biomechanical repercussion of betamethasone-induced osteopenia in growing rat femurs. Bone Miner 1993;20:265-76.
33. Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994;55 273-86.